Tonse, Raees
Rubens, Muni
Appel, Haley
Tom, Martin C.
Hall, Matthew D.
Odia, Yazmin
McDermott, Michael W.
Ahluwalia, Manmeet S.
Mehta, Minesh P.
Kotecha, Rupesh
Article History
Received: 7 September 2021
Accepted: 27 October 2021
First Online: 8 November 2021
Declarations
:
: Conflicts of Interest: R. Tonse: None M. Rubens: None H. Appel: Consulting for Novocure M. Tom: Institutional research funding from Blue Earth Diagnostics Ltd. M. Hall: Honorarium from Accuray, Inc. Proton Collaborative Group Executive Committee Institutional Representative and Voting Member, Miami Cancer Institute (unpaid). Grant Funding: Live Like Bella Pediatric Cancer Research Initiative, Florida Department of Health Grant 8LA04. Y. Odia: No conflicts of interest; Trial Support (BMS, Novocure), DSMC (GammaTile, Actuate, Oncoceutics/Chimerix) M. W. McDermott: Consulting for Deinde Medical and Stryker Corporation M. S. Ahluwalia: Receipt of grants/research supports: Astrazeneca, BMS, Bayer, Incyte, Pharmacyclics, Novocure, Mimivax, Merck. Receipt of honoraria or consultation fees: Bayer, Novocure, Kiyatec, Insightec, GSK, Nuvation, Cellularity, Apollomics. Stock shareholder: Doctible, Mimivax, Cytodyn. M.P. Mehta: Consulting for Karyopharm, Sapience, Zap, Mevion. Board of Directors: Oncoceutics. R. Kotecha: Honoraria from Accuray Inc., Elekta AB, Viewray Inc., Novocure Inc., Elsevier Inc. Institutional research funding from Medtronic Inc., Blue Earth Diagnostics Ltd., Novocure Inc., GT Medical Technologies, Astrazeneca, Exelixis, Viewray Inc.